# Comparing Two Surgical Approaches Using Cross-Linked Hyaluronic Acid-Biofunctionalized Alloplast Particulate in Sinus Floor Elevation: A Randomized Clinical Trial

**Authors:** Chantal Wittmers, Anton Friedmann, Andreas van Orten, Bashar Husseini, Werner Götz

PMC · DOI: 10.3390/jfb17020086 · 2026-02-09

## TL;DR

This study compares two surgical methods for sinus floor elevation using a biofunctionalized material, finding both safe and effective for bone regeneration.

## Contribution

The study introduces a novel biofunctionalized alloplast particulate with cross-linked hyaluronic acid for sinus floor elevation and compares two surgical techniques.

## Key findings

- Both surgical approaches resulted in successful implant integration and 100% implant survival after one year.
- New bone formation was observed histologically in all samples, with an average of 61.17% new bone in the analyzed areas.
- The transcrestal approach required additional augmentation, while the lateral approach allowed implant placement without it in some cases.

## Abstract

Objective: The purpose of this study was to assess the outcome of sinus grafting with a beta-tricalcium phosphate/hydroxyapatite (ß-TCP/HA) alloplast particulate biofunctionalized with cross-linked hyaluronic acid (xHya), comparing two surgical access techniques. Clinical, histological, histochemical, immunohistochemical and histomorphometrical parameters were used to characterize the tissue samples, which were retrieved at the second surgery for implant placement five months after sinus floor elevation (SFE). Materials and Methods: Twenty patients with a residual bone height ≤ 4 mm, estimated by a Cone Beam Computed Tomography (CBCT), were randomly allocated either to an innovative transcrestal sinus floor elevation (tSFE = tests) approach or a conventional lateral window approach (lSFE = controls) using piezoelectric preparation. The tSFE was carried out using the hydraulic Jeder®-System. Grafting in both groups was performed using a ß-TCP–HA combination, which was biofunctionalized with a cross-linked hyaluronic acid. For both access techniques, a cross-linked collagen membrane covered either the bone window or transcrestal osteotomy. For second-stage surgery, a second CBCT was used to assess the bone volume and possible implant positioning to compare it with the baseline CBCT. Bone cores were harvested at implant placement and evaluated histomorphometrically. Patients were followed for 1-year post-op for survival rate estimation. Non-superiority was hypothesized for both surgical methods; thus, the primary outcome measure assessed different discomfort levels using patient-reported outcome measures (PROMs) for each therapeutic approach. Secondary outcomes were the volume change in subantral bone after sinus floor elevation, the chance of placing a 10 mm long implant with no need for additional augmentation, histological evaluation of the newly gained tissue, and implant integration and one-year survival. Results: Eighteen patients (n = 18/20) qualified for implant placement at five months, and ten donated tissue biopsies for microscopic analysis. Primary outcome reporting using PROMs was discarded due to truncated patient enrollment. The secondary parameter, placement of a ≥10 mm long implant without additional augmentation, was achieved for nine sites/patients from the lSFE control group. All patients from the tSFE test group received an implant that was positioned alongside additional augmentation. In both groups, all implants integrated and were functionally loaded. A total of 10 core samples (3 from the tSFE group and 7 from the lSFE group) were obtained and analyzed. Microscopically, new bone formation appeared consistent in all obtained samples. Specimens revealed advanced and ongoing osteogenesis, with most histological markers reacting positively in the immunohistochemical (IHC) staining. The histomorphometric calculation revealed that a mean of 61.17 ± 16.55% of the total area was occupied by newly formed bone, 30.43 ± 10.09% by connective tissue and 8.92 ± 15.29% by residual graft substitute. One-year follow-up of the loaded implants showed a 100% implant survival rate. Conclusions: Biofunctionalizing ß-TCP + HA particulate with cross-linked hyaluronic acid in sinus floor elevation procedures appears to be a safe and beneficial approach, resulting in satisfactory clinical, radiographic and histological parameters. In our study population, which presented with very atrophic residual subantral bone conditions, the hydrodynamic transcrestal sinus floor elevation method required a back-up treatment by the conventional lateral approach.

## Linked entities

- **Chemicals:** beta-tricalcium phosphate (PubChem CID 24456), hydroxyapatite (PubChem CID 14781)

## Full-text entities

- **Genes:** EDA (ectodysplasin A) [NCBI Gene 1896] {aka ECTD1, ED1, ED1-A1, ED1-A2, EDA-A1, EDA-A2}, BGLAP (bone gamma-carboxyglutamate protein) [NCBI Gene 632] {aka BGP, OC, OCN}, VWF (von Willebrand factor) [NCBI Gene 7450] {aka F8VWF, VWD}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, RUNX2 (RUNX family transcription factor 2) [NCBI Gene 860] {aka AML3, CBF-alpha-1, CBFA1, CCD, CCD1, CLCD}, ALPP (alkaline phosphatase, placental) [NCBI Gene 250] {aka ALP, PALP, PLAP, PLAP-1}, TRAP [NCBI Gene 100187907], SPP1 (secreted phosphoprotein 1) [NCBI Gene 6696] {aka BNSP, BSPI, ETA-1, OPN}
- **Diseases:** SFE (MESH:D059952), periimplantitis (MESH:D057873), membrane rupture (MESH:D005322), atrophic subantral bone condition (MESH:D001847), periodontitis (MESH:D010518), Inflammation (MESH:D007249), injuries (MESH:D014947), tooth loss (MESH:D016388), rupture (MESH:D012421)
- **Chemicals:** zirconia (MESH:C028541), Ribose (MESH:D012266), Periodic Acid (MESH:D010504), Eosin (MESH:D004801), alcohol (MESH:D000438), Hematoxylin (MESH:D006416), DPBM (-), H.E. (MESH:D006371), hydroxyapatite (MESH:D017886), water (MESH:D014867), clindamycin (MESH:D002981), Cerasorb (MESH:C485817), amoxicillin (MESH:D000658), Hyaluronic Acid (MESH:D006820), calcium sulfate (MESH:D002133), chlorhexidine (MESH:D002710), Midazolam (MESH:D008874), sugar (MESH:D000073893), paraffin (MESH:D010232), Ibuprofen (MESH:D007052), NaCl (MESH:D012965), xylol (MESH:D014992), EDTA (MESH:D004492)
- **Species:** Bos taurus (bovine, species) [taxon 9913], Homo sapiens (human, species) [taxon 9606]

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12941864/full.md

---
Source: https://tomesphere.com/paper/PMC12941864